Abacus Global CEO on record 2025 growth – ICYMI

Abacus Global Management reported record 2025 results, delivering >100% year-over-year growth in EBITDA, adjusted net income, and gross results, driven by momentum in the expanding life settlements market. CEO Jay Jackson highlighted the doubling of key financial metrics, indicating strong operational leverage and rapid market growth. The results are likely to positively affect ABX’s earnings trajectory and investor sentiment, and could move the stock meaningfully on the news.

Analysis

Winners extend beyond the headline equity: originators with scale (who control sourcing and medical/forensic underwriting), specialty lenders that fund policies, and boutique securitization desks that can arbitrage term premiums against long-dated ABS demand. Second-order beneficiaries include actuarial/data vendors, M&A advisers working on roll-ups, and structured credit desks that can warehouse senior tranches; conversely, traditional life insurers face margin squeeze where policy buyouts become a capital management tool, pressuring spreads on new business.

Key tail risks cluster around three levers: realized mortality vs modeled mortality (medical breakthroughs or unexpectedly rapid longevity improvements), interest-rate compression that narrows funding spreads, and regulatory or litigation shocks (state insurance law changes, transfer-tax/legal challenges). Timeframes differ: equity momentum can persist for months on securitization windows and favorable funding; mortality/medical trends play out over years and can permanently reprice the asset class; regulatory/legal events can trigger swift de-rating in days-weeks.

Actionable trade framing should isolate exposure to origination/scale and to balance-sheet funding. Favored asymmetric exposure is an equity-plus-options stitch on the consolidation leader (ABL) sized to event risk: long-dated call exposure to capture multiple expansion from durable scale, hedged with a small short-dated put to monetize near-term strength while defining downside. For credit-oriented allocations, prefer senior/AAA tranches of newly issued life-settlement ABS or private floating-rate warehouse financings to capture carry with limited mortality bucket exposure.

Consensus blind spot: headlines conflate volume growth with durable economics — rapid origination can mask deteriorating selection and rising unrecognized reserves. The market may be underpricing originator operational risk (underwriting loosening) and funding roll/rehypothecation risk if wholesale credit dries up. Monitor vintage-level IRR, securitization spreads, and medical-case-aging metrics — these will be the canaries before headline growth reverses.

Key Decisions for Investors

• Long ABL (ABL) equity — 12–18 month horizon. Target 30–60% upside vs current levels if securitization windows stay open and funding spreads hold; size 2–4% NAV with a 25% stop-loss. Catalyst list: successful ABS placement, stable warehouse financing spreads, and margin accretion in next two quarters.
• Options stitch on ABL — buy 18-month/Jan-2028 calls at-the-money and fund ~25% of cost by selling short-dated (30–60 day) puts. R/R: asymmetric upside capture while collecting premium; max loss = premium paid, roll down if fundamentals falter.
• Pair trade: long ABL (1) / short a large traditional life insurer (e.g., LNC or MET) (0.6) — 6–12 month horizon. Isolates life-settlement origination outperformance vs legacy insurers; risk is correlated macro shocks (rates, contagion), hedge with interest-rate swap exposure if rates move sharply.
• Allocate to senior tranches of life-settlement ABS or private warehouse financing — 2–4 year horizon. Target nominal yields of LIBOR/Fed funds + 350–600bps with loss assumptions stressed to +30% mortality adverse deviation; cap allocation at 5% of credit sleeve until vintage-level loss rates are observable.